Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human Phase 1 clinical trial of APTN-101 program in glioblastoma (GBM).

Next Previous
Trial Profile

A first-in-human Phase 1 clinical trial of APTN-101 program in glioblastoma (GBM).

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APTN 101 (Primary)
  • Indications Glioblastoma; Glioma
  • Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

  • 20 Jan 2026 According to an Adaptin Bio media release, company announced that the Preston Robert Tisch Brain Tumor Center has granted the first Institutional Review Board (IRB) approval for its Phase 1 first-in-human clinical trial evaluating APTN-101 in the treatment of glioblastoma multiforme (GBM).
  • 15 Apr 2025 According to an Adaptin Bio media release, company believe financing, in connection with Adaptin eventual listing on the OTC, will enable company to nitiate our first-in-human Phase 1 clinical trial to evaluate APTN-101.
  • 06 Sep 2024 According to an Adaptin Bio media release, company announced that the FDA has cleared an Investigational New Drug (IND) application for APTN-101 program in glioblastoma (GBM). The clearance will enable the initiation of a first-in-human Phase 1 clinical trial to evaluate this investigational candidate in GBM.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top